Cargando…

Mifepristone for Treatment of Metabolic Syndrome: Beyond Cushing’s Syndrome

A growing body of research indicates that cortisol, the glucocorticoid product of the activation of the hypothalamic-pituitary-adrenal axis, plays a role in the pathophysiology of metabolic syndrome. In this regard, chronic exposure to cortisol is associated with risk factors related to metabolic sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díaz-Castro, Francisco, Monsalves-Álvarez, Matías, Rojo, Leonel E., del Campo, Andrea, Troncoso, Rodrigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193078/ https://www.ncbi.nlm.nih.gov/pubmed/32390830 http://dx.doi.org/10.3389/fphar.2020.00429

Ejemplares similares

THU621 Mifepristone In Exogenous Cushing's Syndrome
por: Priyadarshan, Swetha, et al.
Publicado: (2023)

Hypokalemia associated with mifepristone use in the treatment of Cushing’s syndrome
por: Sai, Katta, et al.
Publicado: (2019)

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome
por: Moraitis, Andreas G., et al.
Publicado: (2016)

Global clinical response in Cushing’s syndrome patients treated with mifepristone
por: Katznelson, Laurence, et al.
Publicado: (2014)

Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance
por: del Campo, Andrea, et al.
Publicado: (2018)

Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations
por: Brown, David R., et al.
Publicado: (2020)

The Development of Hypogonadotropic Hypogonadism After Starting Low Dose Mifepristone for Cushing’s Syndrome
por: Rowell, Jennifer Voigt
Publicado: (2021)

Improvement in Insulin Sensitivity During Mifepristone Treatment of Cushing Syndrome:Early and Late Effects
por: Wallia, Amisha, et al.
Publicado: (2013)

SUN-186 Case Report: Mifepristone Taper in an Individual with Equivocal Cushing’s Syndrome Screening Tests
por: Martin, Christopher, et al.
Publicado: (2020)

Mifepristone induced liver injury in a patient with Cushing syndrome: a case report and review of the literature
por: Ault, Taylor A., et al.
Publicado: (2023)

Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases
por: Chang, Alice Y, et al.
Publicado: (2021)

ODP322 Impact of Mifepristone on Liver Function and Resolution of Liver Steatosis in Patients with Cushing Syndrome – A Case Study
por: East, Honey E, et al.
Publicado: (2022)

Beyond the metabolic syndrome: Visceral and marrow adipose tissues impair bone quantity and quality in Cushing’s disease
por: Batista, Sérgio Luchini, et al.
Publicado: (2019)

Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension
por: Fein, Henry G., et al.
Publicado: (2015)

Unusual Presentation of Cyclic Cushing’s Syndrome
por: Morales Hernandez, Maria del Mar, et al.
Publicado: (2021)

SUN-460 Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
por: Moraitis, Andreas, et al.
Publicado: (2019)

Subclinical Cushing's Syndrome and Metabolic Disorder
por: Bae, Ji Cheol
Publicado: (2014)

Mania as Debut of Cushing's Syndrome
por: Martínez, Ricardo Álvarez, et al.
Publicado: (2020)

A Case of Iatrogenic Cushing’s Syndrome
por: Del Toro Diez, Andrea, et al.
Publicado: (2021)

Severe Cushing’s syndrome and bilateral pulmonary nodules: beyond ectopic ACTH
por: Tavares Bello, Carlos, et al.
Publicado: (2017)

Glucocorticoid Receptor β Overexpression Has Agonist-Independent Insulin-Mimetic Effects on HepG2 Glucose Metabolism
por: Sepúlveda-Quiñenao, Claudia, et al.
Publicado: (2022)

Cushing’s Syndrome Effects on the Thyroid
por: Paragliola, Rosa Maria, et al.
Publicado: (2021)

Chemosensory dysfunction in Cushing’s syndrome
por: Heger, Elena, et al.
Publicado: (2021)

An infant with Cushing syndrome
por: Sng, Andrew, et al.
Publicado: (2015)

Fluconazole and acetazolamide in the treatment of ectopic Cushing's syndrome with severe metabolic alkalosis
por: Schwetz, Verena, et al.
Publicado: (2015)

Cushing's Syndrome and Treatment-Resistant Depression
por: Shukla, Lekhansh
Publicado: (2017)

Recent advances in JAK inhibitors for the treatment of metabolic syndrome
por: Collotta, Debora, et al.
Publicado: (2023)

MON-328 Disorders of Glucose Metabolism in Cushing Syndrome in Uzbekistan
por: Narimova, Gulchekhra Djumaniyazovna, et al.
Publicado: (2020)

Multi-Target Approaches in Metabolic Syndrome
por: Lillich, Felix F., et al.
Publicado: (2021)

Concurrent training and interindividual response in women with a high number of metabolic syndrome risk factors
por: Delgado-Floody, Pedro, et al.
Publicado: (2022)

β-Hydroxybutyrate Increases Exercise Capacity Associated with Changes in Mitochondrial Function in Skeletal Muscle
por: Monsalves-Alvarez, Matías, et al.
Publicado: (2020)

UNUSUAL PRESENTATION OF CUSHING'S SYNDROME
por: Banerjee, Gautam, et al.
Publicado: (1987)

INFANTILE IATROGENIC CUSHING'S SYNDROME
por: Katar, Selahattin, et al.
Publicado: (2008)

Endocrine hypertension – Cushing's syndrome
por: Singh, Yashpal, et al.
Publicado: (2011)

Neuropsychiatric disorders in Cushing's syndrome
por: Pivonello, Rosario, et al.
Publicado: (2015)

Systemic therapy of Cushing’s syndrome
por: Eckstein, Niels, et al.
Publicado: (2014)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

Cushing's syndrome, pheochromocytoma, or both?
por: Kullamaa, Liisa, et al.
Publicado: (2023)

Ectopic Cushing syndrome in Colombia
por: Lopez-Montoya, Vanessa, et al.
Publicado: (2020)

Musculoskeletal complications of Cushing syndrome
por: Leszczyńska, Dorota, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l3p5k7ocbcebk57c1o8u367iqp